Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

PurposeThis research investigated the predictive role of metabolic syndrome (MetS) in breast cancer neoadjuvant chemotherapy (BCNACT) response.MethodsOne hundred fifty primary breast cancer (BC) patients who underwent neoadjuvant chemotherapy (NACT) were included retrospectively. MetS, MetS componen...

Full description

Bibliographic Details
Main Authors: Ying Lu, Pinxiu Wang, Ning Lan, Fei Kong, Awaguli Abdumijit, Shiyan Tu, Yanting Li, Wenzhen Yuan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
breast cancer
metabolic syndrome
neoadjuvant chemotherapy
efficacy prediction
MP grading
RECIST criteria
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.899335/full

Similar Items

Similar Items